Biology Respiration in Plants part 17 (Fermentation : alcohol, lactic acid) CBSE class 11 XI Biology Respiration in Plants part 17 (Fermentation : alcohol, lactic acid) CBSE class 11 XI. By: ExamFearVideos … Continue reading →

Biology Plant Growth Development part 4 (Arithematic Growth Rate ) CBSE class 11 XI Biology Plant Growth Development part 4 (Arithematic Growth Rate ) CBSE class 11 XI. By: ExamFearVideos … Continue reading →

REGINA MEDINA, Daily News Staff Writer medinar@phillynews.com, 215-854-5985 Posted: Friday, February 13, 2015, 12:16 AM OVERBROOK HIGH School has not had a biology-certified teacher since September. The 129 students enrolled in biology, instead, have seen their teachers reassigned, classes changed and little instruction in the biology lab since the fall for a course that is a state requirement for high school graduation. And the biology-certified teacher set to begin today at Overbrook, according to a school district official who spoke earlier this week to Philadelphia magazine, has rejected an offer to teach at the school, the district confirmed yesterday. "The candidate declined for personal reasons," said district spokeswoman Raven Hill. The district will continue to seek a biology-certified teacher for Overbrook, she said, adding "this issue highlights the difficulty of recruiting candidates midyear for traditionally hard-to-fill positions." While the search continues, the class that the 10th-grade students initially enrolled in as biology had its title changed in the fall to "environmental science," Overbrook staffers say. The reason behind the change was so the "children wouldn't be forced to take a test they didn't have the education for," said an Overbrook source, speaking anonymously for fear of retribution. When report cards … Continue reading →

I have a biology degree, okay? Sen. Rand Paul (R-Ky), remarks at the Lincoln Labs Reboot Congress conference, Feb. 12, 2015 This column has been updated with an additional explanation by Pauls spokesman We first spotted a version of this quote in a Bloomberg column by David Weigel, and then checked the quotes with our colleague Jose DelReal, who had attended the conference. This is a bit of an odd one, given that Paul does not have a college undergraduate degree. Paul mentioned his alleged degree at the conference not once, but twice. First, in an exchange with TechCrunch founder Michael Arrington, Paul said: Arrington: Lets talk about economics because maybe you can actually explain this to me. I have an econ degree which means I know just enough not to understand any of what our government is [inaudible] Paul: Mines in biology and English so this is going to be a great conversation. Then, later in the conversation, expounding on what he considered the virtues of Bitcoin, Paul said: This is just me. I have a biology degree, okay? But with Bitcoin my concern always was whether or not something has real value. So I could imagine a kind … Continue reading →

- Bringing New Generation of Orally Delivered Biotherapeutics GERMANTOWN, Maryland and GHENT, Belgium, Feb. 13, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has entered into a definitive agreement to acquire ActoGeniX, a European clinical stage biopharmaceutical company forging a new frontier in cellular therapeutics. The proprietary TopAct platform developed by ActoGeniX enables the molecular engineering of food-grade microbes (Lactococcus lactis) to generate biologically-contained ActoBiotics for in situ expression and secretion of novel biotherapeutic proteins and peptides including cytokines, enzymes, hormones, and monoclonal antibodies to the oral and gastrointestinal tract. This groundbreaking class of orally available biopharmaceuticals has the potential to facilitate targeted therapies against oral, gastrointestinal, metabolic, allergic and autoimmune diseases. Logo - http://photos.prnewswire.com/prnh/20130919/NY83283LOGO Intrexon's exclusive channel collaborators currently utilize the Company's suite of technologies in cellular and gene therapies for cancer, orphan genetic disorders, blindness, infectious diseases, tissue repair, as well as synthetic biology-mediated production of APIs. The addition of the ActoGeniX platform brings two more clinical stage assets to the Intrexon portfolio, and complements the broad collection of tools available for current and future partners to enable innovative solutions for the next generation of biotechnology. ActoBiotics offer the unique ability … Continue reading →